SCHEMBL6349239

SCHEMBL6349239

COCCC(C(N)=O)N(CC(=O)c1ccccc1)C(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 4/20 0.38
TRPM8 Q7Z2W7 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
HTT P42858 2/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NPC1 O15118 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
MAPK1 P28482 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
AGTR1 P30556 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350103 0.90 ALDH1A1 (0.40) POLBKDM4EALDH1A1USP2LMNA
SCHEMBL6349644 0.90 KDM4E (0.40) POLBKDM4EALDH1A1USP2LMNA
SCHEMBL6351176 0.82 TRPM8 (0.44) KDM4EALDH1A1USP2KMT2ATRPM8
SCHEMBL6360094 0.81 KDM4E (0.42) POLBKDM4EALDH1A1USP2LMNA
SCHEMBL6350920 0.80 ALDH1A1 (0.41) KDM4EALDH1A1USP2LMNAKMT2A
SCHEMBL6358138 0.78 TRPM8 (0.51) KDM4EALDH1A1USP2KMT2ATRPM8
SCHEMBL6347733 0.74 ALDH1A1 (0.43) KDM4EALDH1A1USP2LMNAKMT2A
SCHEMBL6354208 0.74 ALDH1A1 (0.43) KDM4EALDH1A1USP2LMNAKMT2A
SCHEMBL6347856 0.74 ALDH1A1 (0.43) KDM4EALDH1A1USP2LMNAKMT2A
SCHEMBL6345185 0.74 KDM4E (0.45) KDM4EALDH1A1USP2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 POLB 3917/4885KDM4E 2934/4885ALDH1A1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.